A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations

Exclusion Criteria

• •Known hypersensitivity to erlotinib or any of its excipients
• •Squamous non-small cell or small cell tumors or absence of histological report
• •Neoadjuvant/adjuvant chemotherapy within 6 months prior to enrollment
• •Prior exposure to inhibitors of EGFR
• •Prior chemotherapy or treatment with another systemic anti-cancer agent for the treatment of the participant's current stage of disease
• •Any significant ophthalmologic abnormality, especially severe dry eye syndrome, keratoconjunctivitis sicca, Sjögren syndrome, severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions
• •Radical radiotherapy with curative intent within 28 days prior to enrollment
• •Any active non-controlled systemic disease